ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Apnimed
28.03
-0.5200
-1.82%
盤後:
27.58
-0.4500
-1.61%
19:59 EDT
成交量:
24.63萬
成交額:
694.87萬
市值:
11.16億
市盈率:
-35.08
高:
29.56
開:
28.60
低:
27.64
收:
28.55
52周最高:
35.29
52周最低:
16.12
股本:
3,982.32萬
流通股本:
1,200.00萬
量比:
0.59
換手率:
2.05%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.7990
每股收益(LYR):
-23.7581
淨資產收益率:
--
總資產收益率:
-36.94%
市淨率:
-3.67
市盈率(LYR):
-1.18
資料載入中...
總覽
公司
新聞資訊
公告
公司資料
公司名字:
Apnimed
交易所:
NASDAQ
成立時間:
2017
員工人數:
65
公司地址:
39 John F. Kennedy Street,4th Floor,Cambridge,Massachusetts,United States
官網:
http://www.apnimed.com
郵編:
02138
電話:
617 500 8880
傳真:
- -
簡介:
Apnimed, Inc.於2017年6月根據特拉華州法律成立。該公司是一家後期臨床製藥公司,致力於發現、開發和商業化新型口服療法,解決睡眠相關呼吸疾病的神經生物學問題。其唯一的臨床候選產品Oxnimbi是一種研究性固定劑量抗呼吸暫停神經肌肉調節劑,結合新型抗毒蠅鹼和選擇性去甲腎上腺素再攝取抑製劑,旨在通過改善上氣道肌肉活動來治療阻塞性睡眠呼吸暫停,以維持氣道通暢並防止睡眠期間氣道塌陷,並於2026年4月向FDA提交了一份新藥申請。
董事
名稱
職位
Kevin R. Lind
Chief Executive Officer and Director
Chris Dimitropoulos
Independent Director
Gary Sender
Independent Director
Lawrence G. Miller
Director and Vice Chair
Paul Fonteyne
Independent Director
Paul Sekhri
Board Chair and Director
股東
名稱
職位
Kevin R. Lind
Chief Executive Officer and Director
Dennis P. Molnar
Chief Operating Officer and President
Michael Kelly
Chief Financial Officer
Barry Wohl
Chief Business Officer
Beth Weinberg
Chief Regulatory and Safety Officer
Graham Goodrich
Chief Commercial Officer
John Cronin
Chief Medical Officer
Luigi Taranto Montemurro
Chief Scientific Officer
Steven Spector
Chief Legal Officer and Head of Corporate Affairs
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/APMD/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"APMD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APMD\",,,,,undefined,":{"symbol":"APMD","market":"US","secType":"STK","nameCN":"Apnimed","latestPrice":28.03,"timestamp":1787342400000,"preClose":28.55,"halted":0,"volume":246332,"hourTrading":{"tag":"盘后","latestPrice":27.58,"preClose":28.03,"latestTime":"19:59 EDT","volume":7596,"amount":212454.87,"timestamp":1787356799532,"change":-0.45,"changeRate":-0.016054,"amplitude":0.016054},"delay":0,"changeRate":-0.018213660245183873,"floatShares":12000000,"shares":39823183,"eps":-0.799,"marketStatus":"休市中","change":-0.52,"latestTime":"08-21 16:00:00 EDT","open":28.6,"high":29.56,"low":27.64,"amount":6948736.033568,"amplitude":0.06725,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.799,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1785470400000,"exchange":"NASDAQ","adjPreClose":28.55,"preHourTrading":{"tag":"盘前","latestPrice":28.95,"preClose":28.55,"latestTime":"08:19 EDT","volume":93,"amount":2692.35,"timestamp":1787314764839,"change":0.4,"changeRate":0.014011,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":27.58,"preClose":28.03,"latestTime":"19:59 EDT","volume":7596,"amount":212454.87,"timestamp":1787356799532,"change":-0.45,"changeRate":-0.016054,"amplitude":0.016054},"volumeRatio":0.590759637683797},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APMD\",,,,,undefined,":{"symbol":"APMD","floatShares":12000000,"roa":"-36.94%","roe":"--","lyrEps":-23.758134,"volumeRatio":0.590759637683797,"shares":39823183,"dividePrice":0,"high":29.56,"amplitude":0.06725,"preClose":28.55,"low":27.64,"week52Low":16.12,"pbRate":"-3.67","psRate":"9.29","week52High":35.29,"institutionHeld":0,"latestPrice":28.03,"eps":-0.799,"divideRate":0,"volume":246332,"delay":0,"ttmEps":-0.799,"open":28.6,"prevYearClose":16,"prevWeekClose":31.75,"prevMonthClose":25,"prevQuarterClose":16,"fiveDayClose":31.75,"twentyDayClose":16,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APMD\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APMD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APMD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APMD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APMD","date":"2026-08-21","current":-35.081352,"percent":0,"low":-12.343549,"twenty":-9.895607,"median":-8.661063,"eighty":-7.942829,"high":-7.725991,"avg":-8.97211,"sd":1.217242,"marketCap":1582331874},"quantilePoints":[{"date":"2026-08-07","current":-8.661063,"twenty":-8.320585,"median":-7.986942,"eighty":-7.766377,"marketCap":1110270342},{"date":"2026-08-14","current":-8.943759,"twenty":-8.664791,"median":-8.256435,"eighty":-7.766377,"marketCap":1146509438},{"date":"2026-08-21","current":-12.343549,"twenty":-9.895607,"median":-8.661063,"eighty":-7.942829,"marketCap":1582331874}],"updateTime":1787508177716},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":573282303,"yearFounded":2017,"employeeNum":65,"address":"39 John F. Kennedy Street,4th Floor,Cambridge,Massachusetts,United States","zipCode":"02138","officePhone":"617 500 8880","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.apnimed.com","stockEarnings":[{"period":"1week","weight":-0.1172},{"period":"1month","weight":0.7519},{"period":"ytd","weight":0.7519}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Apnimed, Inc.於2017年6月根據特拉華州法律成立。該公司是一家後期臨床製藥公司,致力於發現、開發和商業化新型口服療法,解決睡眠相關呼吸疾病的神經生物學問題。其唯一的臨床候選產品Oxnimbi是一種研究性固定劑量抗呼吸暫停神經肌肉調節劑,結合新型抗毒蠅鹼和選擇性去甲腎上腺素再攝取抑製劑,旨在通過改善上氣道肌肉活動來治療阻塞性睡眠呼吸暫停,以維持氣道通暢並防止睡眠期間氣道塌陷,並於2026年4月向FDA提交了一份新藥申請。","exchange":"NASDAQ","name":"Apnimed","nameEN":"Apnimed"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"APMD\",market:\"US\",,,undefined,":{"directors":[{"name":"Kevin R. Lind","position":"Chief Executive Officer and Director"},{"name":"Chris Dimitropoulos","position":"Independent Director"},{"name":"Gary Sender","position":"Independent Director"},{"name":"Lawrence G. Miller","position":"Director and Vice Chair"},{"name":"Paul Fonteyne","position":"Independent Director"},{"name":"Paul Sekhri","position":"Board Chair and Director"}],"executives":[{"name":"Kevin R. Lind","position":"Chief Executive Officer and Director"},{"name":"Dennis P. Molnar","position":"Chief Operating Officer and President"},{"name":"Michael Kelly","position":"Chief Financial Officer"},{"name":"Barry Wohl","position":"Chief Business Officer"},{"name":"Beth Weinberg","position":"Chief Regulatory and Safety Officer"},{"name":"Graham Goodrich","position":"Chief Commercial Officer"},{"name":"John Cronin","position":"Chief Medical Officer"},{"name":"Luigi Taranto Montemurro","position":"Chief Scientific Officer"},{"name":"Steven Spector","position":"Chief Legal Officer and Head of Corporate Affairs"}]}}}